Ichan School of Medicine: A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows
November 15, 2020
November 15, 2020
NEW YORK, Nov. 15 (TNSJou) -- The Ichan School of Medicine at Mount Sinai issued the following news release:
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol--the so-called "bad" cholesterol--by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study spons . . .
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol--the so-called "bad" cholesterol--by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study spons . . .